NCT02807844 - Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | Biotech Hunter

Enrollment

141

Participants

Timeline

Start Date

June 29, 2016

Primary Completion Date

June 4, 2020

Study Completion Date

June 4, 2020

Conditions

Triple Negative Breast CancerPancreatic CarcinomaMelanomaEndometrial Carcinoma

Interventions

DRUG

MCS110

MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.

DRUG

PDR001

MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.

Trial Locations (20)

2610

Novartis Investigative Site, Wilrijk

7000

Novartis Investigative Site, Chur

8091

Novartis Investigative Site, Zurich

20133

Novartis Investigative Site, Milan

20141

Novartis Investigative Site, Milan

28009

Novartis Investigative Site, Madrid

38138

The West Clinic, Germantown

44805

Novartis Investigative Site, Saint-Herblain

46010

Novartis Investigative Site, Valencia

60590

Novartis Investigative Site, Frankfurt

63123

Washington University School of Medicine, St Louis

77030

MD Anderson Cancer Center, Houston

89081

Novartis Investigative Site, Ulm

02215

Dana Farber Cancer Center, Boston

FIN-00029

Novartis Investigative Site, HUS

Unknown

Novartis Investigative Site, Hong Kong

135 8550

Novartis Investigative Site, Koto Ku

03080

Novartis Investigative Site, Seoul

05505

Novartis Investigative Site, Seoul

CH 1211

Novartis Investigative Site, Geneva